Drugs / Meperizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05353179 | Jun → Oct 2022 | granulomatosis with polyangiitis, hemophagocytic syndrome | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meperizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05353179 ↗ |
| Modality | Monoclonal antibody | “Meperizumab injection is a humanized monoclonal antibody of IgG1 injection” NCT05353179 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of meperizumab once” NCT05353179 ↗ |